SSY Group says China NMPA clears generic consistency review for diltiazem tablets 30 mg

• China’s NMPA cleared SSY Group’s diltiazem hydrochloride tablets (30 mg) under its generic drug consistency evaluation program.
• The drug is used to treat angina pectoris and mild to moderate essential hypertension.
• The clearance complements the group’s earlier production and registration approval for diltiazem hydrochloride injection, supporting a combined inpatient-outpatient regimen.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260902-12315941), on September 02, 2026, and is solely responsible for the information contained therein.